The Qingdao Port Health Study
2016年8月10日 更新者：China National Center for Cardiovascular Diseases
China, efforts are underway to respond to an unprecedented epidemiologic transition, with soaring rates of cardiovascular disease (CVD), including heart disease and stroke.
Yet there may be limitations in translating observations and findings derived from Anglo-based population studies.
As such, there is a critical need for population-based studies that provide insight into the risk factors, incidence, and outcomes of CVD in China.
The Qingdao Port Health Study is a population-based prospective cohort study of employees of the Qingdao Port Group, China, designed to investigate the burden of CVD and risk factors (e.g., sociodemographic, biological, environmental and clinical factors) associated with disease onset and outcomes.
研究概览
地位
完全的
条件
详细说明
In Qingdao Port, annual health assessments are offered at 3 on-site health clinics.
The annual health assessment consists of a questionnaire, physical examination, laboratory tests, bio-sampling, and imaging examinations.In each year, demographics information, medical history, medication use and adherence, family history,lifestyles (e.g., nutritional intake; physical activity; smoking; alcohol use/abuse), menopause (including hormone use) and quality of life were collected by trained researchers.In 2013, blood and saliva samples were collected.
Follow-up health assessments are performed every year.
The outcomes of cardiovascular disease (angina, myocardial infarction, heart failure, stroke, revascularization), non-communicable diseases (chronic obstructive pulmonary disease, renal failure, liver disease and cancer), and all-cause death are collected from local medical insurance database.This study aim to surveillance of cardiovascular and other non-communicable diseases (risk factors, health outcomes and trends) and investigate of socio-cultural, biological, behavioral, social, and environmental factors on work performance, cardiovascular disease onset and cardiovascular health outcomes.
研究类型
观察性的
注册 (实际的)
25000
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Employees and retirees in Qingdao Port Group, Shandong province, China
描述
Inclusion Criteria:
- All employees and retirees in Qingdao Port Group
- Aged over 18 years old
Exclusion Criteria:
-
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
all cause mortality
大体时间：3 year
|
The number of all cause death will be collected.
The effects of modified risk factors on all cause mortality will be assessed.
|
3 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Heart diseases (defined as myocardial infarction, agina requiring hospitalization and acute/chronic heart failure)
大体时间：3 year
|
The number of heart disease outcomes will be collected because one person may have more than one time heart diseases.
The incidence of heart disease is calculated by dividing the number of heart disease outcomes by the total number of participants in baseline study.
|
3 year
|
|
stroke (defined as ischemic stroke and hemorraghic stroke)
大体时间：3 year
|
The number of stroke outcomes will be collected.
The incidence of stroke is calculated by dividing the number of stroke outcomes by the total number of participants in baseline study.
|
3 year
|
|
revascularization (defined as percutaneous coronary intervention, coronary artery bypass grafting and percutaneous transluminal coronary angioplasty)
大体时间：3 year
|
The number of revascularizations will be collected, one person may receive more than one time revascularizations.
The incidence of revascularization is calculated by dividing the number of revascularization outcomes by the total number of participants in baseline study.
|
3 year
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
chronic obstructive pulmonary disease
大体时间：3 year
|
The number of participants with chronic obstructive pulmonary disease (COPD) will be collected.
The incidence of COPD is calculated by dividing the number of COPD by the total number of participants in baseline study.
|
3 year
|
|
chronic renal insufficiency
大体时间：3 year
|
The number of participants with chronic renal insufficiency will be collected.
The incidence of chronic renal insufficiency is calculated by dividing the number of chronic renal insufficiency by the total number of participants in baseline study.
|
3 year
|
|
chronic liver diseases (defined as cirrhosis and hepatic failure)
大体时间：3 year
|
The number of chronic liver diseases will be collected.
The incidence of chronic liver diseases is calculated by dividing the number of chronic liver diseases by the total number of participants in baseline study.
|
3 year
|
|
cancer (defined as cancer, recurrence of cancer and cancer metastasis)
大体时间：3 year
|
The number of cancer outcomes will be collected.
The incidence of cancer is calculated by dividing the number of cancer outcomes by the total number of participants in baseline study.
|
3 year
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员：Lixin Jiang, MD, PhD、Fuwai Hospital
- 首席研究员：Xiancheng Liu, MD, PhD、Qingdao Fuwai Hospital
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2013年3月1日
初级完成 (实际的)
2016年1月1日
研究完成 (实际的)
2016年1月1日
研究注册日期
首次提交
2014年12月20日
首先提交符合 QC 标准的
2014年12月30日
首次发布 (估计)
2015年1月1日
研究记录更新
最后更新发布 (估计)
2016年8月11日
上次提交的符合 QC 标准的更新
2016年8月10日
最后验证
2016年1月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.